Aurora Cannabis’s Valuation Compared to Its Peers



Aurora Cannabis’s valuation

Since Aurora Cannabis (ACB) has risen almost 80% in 2019, let’s look at how the company’s valuation stacks up against its peers and its historical average. As of April 8, Aurora Cannabis was trading at a forward EV-to-sales multiple of 14.3x, which was above the peer median of 6.2x. The peers’ median includes companies like Canopy Growth (WEED), Tilray (TLRY), and Aphria (APHA).

Article continues below advertisement

High valuation?

Aurora Cannabis’s multiple essentially means that at the current levels, investors are paying ~14.3 times per unit of the company’s next 12-month sales. On average, the company’s peers were paid just about six times per unit of sales during the same period. Aurora Cannabis was also trading at a premium to its historical two-year average of 10.3x.

Aurora Cannabis was trading at an EV-to-EBITDA multiple of 59x compared to peers’ median of 24x. The company was also trading at a premium to its historical average multiple of 32.4x over the past two-year period. Aurora Cannabis’s valuation has increased over the past year. The company is establishing a prominent position in the Canadian and global cannabis market.

Read Do WEED, ACB, TLRY, and APHA Look Attractive at These Valuations? to compare Aurora Cannabis’s valuation with its peers (HMMJ).


More From Market Realist